After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

Gilead Sciences. “Once-yearly lenacapavir, if approved, could become an important new HIV prevention option that could help address PrEP adherence and persistence challenges for individuals who ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...